Oramet Plus2 mg+500 mg

Oramet Plus is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Evidence-based use classification

• Established/approved use: Oramet Plus is approved for patients with type 2 diabetes mellitus who are already being treated with a combination of rosiglitazone and metformin, or whose blood glucose is not adequately controlled on metformin alone or a thiazolidinedione alone, and for whom treatment with both components is considered appropriate.
• Combination therapy requirement: Oramet Plus is a fixed-dose combination and is not intended as first-line initial therapy for treatment-naive patients; it is generally used after monotherapy with either metformin or rosiglitazone has proven inadequate.
• Not indicated for: Oramet Plus is not indicated for type 1 diabetes mellitus or for treatment of diabetic ketoacidosis.

Because of cardiovascular safety concerns associated with rosiglitazone, use of Oramet Plus is subject to significant prescribing restrictions or has been withdrawn in a number of countries; prescribers should confirm current local regulatory status and reserve Oramet Plus for patients in whom other options are unsuitable.

Each tablet of Rosiglitazone + Metformin Hydrochloride contains two active ingredients:

• Rosiglitazone (as rosiglitazone maleate) – a thiazolidinedione insulin-sensitizing agent, commonly available in strengths such as 1 mg, 2 mg, or 4 mg per tablet in combination products.
• Metformin Hydrochloride – a biguanide antihyperglycemic agent, commonly available in strengths such as 500 mg or 1000 mg per tablet in combination products.

Exact strength combinations vary by manufacturer and market; the prescribing physician selects the appropriate strength based on the patient's current individual component doses.

Oramet Plus is a fixed-dose combination oral antidiabetic medicine that combines two agents with complementary mechanisms of action for the management of type 2 diabetes mellitus.

Rosiglitazone belongs to the thiazolidinedione (TZD) class and works by improving insulin sensitivity in peripheral tissues, while metformin belongs to the biguanide class and primarily works by reducing hepatic glucose production. Combining the two components in a single tablet can help improve treatment adherence in patients who require both agents for adequate glycemic control.

Oramet Plus does not replace a comprehensive diabetes management plan that includes diet, exercise, and regular blood glucose monitoring.

Oramet Plus belongs to the therapeutic class of combination oral antidiabetic agents (thiazolidinedione + biguanide), used in the management of type 2 diabetes mellitus.

Rosiglitazone + Metformin Hydrochloride combines two antihyperglycemic agents with distinct and complementary mechanisms of action:

Rosiglitazone (Thiazolidinedione)

Rosiglitazone is a selective agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Activation of PPAR-gamma in adipose tissue, skeletal muscle, and liver improves insulin sensitivity in peripheral tissues and reduces insulin resistance, thereby improving glycemic control without directly stimulating insulin secretion.

Metformin Hydrochloride (Biguanide)

Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. It does not stimulate insulin secretion and therefore does not typically cause hypoglycemia when used alone.

Together, the two components address both insulin resistance and excessive hepatic glucose output, providing complementary glycemic control in patients with type 2 diabetes mellitus.

Oramet Plus tablets should be taken orally with food (typically with breakfast and/or the evening meal) to minimize gastrointestinal side effects associated with the metformin component. Tablets should be swallowed whole and not split or crushed unless the specific product is scored for splitting. Doses should be spaced evenly through the day as directed by the prescribing physician.

Oramet Plus has clinically significant interactions related to both of its components:

• Iodinated contrast media: Use of intravascular iodinated contrast agents with metformin-containing products such as Oramet Plus increases the risk of contrast-induced nephropathy and metformin-associated lactic acidosis. Oramet Plus should be temporarily discontinued at the time of, or prior to, the procedure and withheld for 48 hours afterward, resuming only after renal function has been re-evaluated and found normal.
• Alcohol: Alcohol potentiates the effect of metformin on lactate metabolism and increases the risk of lactic acidosis; patients should avoid excessive alcohol intake while taking Oramet Plus.
• Cationic drugs eliminated by renal tubular secretion (e.g., cimetidine): May compete with metformin for renal tubular transport, increasing metformin plasma concentrations.
• Drugs that affect glycemic control (e.g., corticosteroids, diuretics, sympathomimetics): May reduce the glucose-lowering effect of Oramet Plus and require closer glycemic monitoring.
• Insulin and other antidiabetic agents: Concurrent use with insulin or insulin secretagogues (e.g., sulfonylureas) may increase the risk of hypoglycemia, and dose adjustment may be needed.
• CYP2C8 inhibitors/inducers (e.g., gemfibrozil, rifampicin): May significantly alter rosiglitazone plasma concentrations; gemfibrozil can increase rosiglitazone exposure while rifampicin can decrease it, requiring dose adjustment and monitoring.

Common and serious side effects reported with Oramet Plus reflect the adverse effect profiles of both components:

Common side effects

• Gastrointestinal upset: nausea, diarrhea, abdominal discomfort, and a metallic taste (metformin component)
• Upper respiratory tract infection
• Headache
• Edema and mild weight gain (rosiglitazone component)
• Mild anemia

Serious side effects (uncommon but require medical attention)

• Lactic acidosis – a rare but life-threatening metabolic complication associated with metformin; symptoms include malaise, muscle pain, respiratory distress, abdominal pain, and unusual sleepiness. Seek immediate medical attention if these occur.
• New-onset or worsening heart failure, sudden weight gain, or fluid retention – associated with rosiglitazone.
• Bone fractures, particularly in women, with long-term use.
• Vitamin B12 deficiency with long-term use, which may present as anemia or peripheral neuropathy.
• Rare reports of myocardial ischemic events have been associated with rosiglitazone in some analyses; discuss cardiovascular risk with your physician.
• Macular edema (rare, associated with thiazolidinediones).

Oramet Plus should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Well-controlled blood glucose is important throughout pregnancy to reduce the risk of complications; however, insulin is generally the preferred agent for achieving glycemic control during pregnancy, and most physicians will switch patients from Oramet Plus to insulin therapy if pregnancy is planned or confirmed.

Regarding breastfeeding, it is not well established whether both components of Oramet Plus pass into breast milk in clinically significant amounts, and use during lactation should only occur after consultation with a physician, weighing the benefits of breastfeeding against the potential risk to the infant. Alternative antidiabetic therapy may be preferred during lactation.

The following precautions and warnings apply to the use of Oramet Plus:

• Cardiovascular risk: Rosiglitazone has been associated in some analyses with a possible increased risk of myocardial ischemic events, and its use is restricted or has been withdrawn in several countries due to these concerns. Oramet Plus should be prescribed only in accordance with current local regulatory guidance, and cardiovascular status should be assessed before and during treatment.
• Fluid retention and heart failure: Oramet Plus can cause or worsen fluid retention, which may lead to or exacerbate heart failure. Patients should be monitored for signs and symptoms of heart failure (e.g., rapid weight gain, edema, shortness of breath), and Oramet Plus should be avoided or used with caution in patients with a history of heart failure (see Contraindications for NYHA Class III/IV).
• Lactic acidosis: A rare but serious risk with the metformin component; risk increases with renal impairment, dehydration, excessive alcohol intake, hepatic impairment, and use of iodinated contrast media (see Interactions and Contraindications).
• Fracture risk: Long-term use of rosiglitazone has been associated with an increased risk of bone fractures, particularly in women; bone health should be considered during long-term therapy.
• Vitamin B12 deficiency: Long-term metformin use may reduce vitamin B12 absorption; periodic monitoring may be considered, particularly in patients with anemia or peripheral neuropathy.
• Hold before contrast procedures and surgery: Oramet Plus should be temporarily discontinued before iodinated contrast procedures and before major surgery, and restarted only after renal function is confirmed to be stable.
• Hepatic function: Liver function should be assessed before starting Oramet Plus and periodically thereafter; the medicine should not be used in patients with active liver disease.
• Ovulation: Thiazolidinediones may result in resumption of ovulation in premenopausal anovulatory women, potentially increasing the risk of unintended pregnancy; adequate contraception should be discussed.

Overdose of Oramet Plus may present with severe hypoglycemia (uncommon, since the components alone rarely cause hypoglycemia unless combined with other antidiabetic agents) or with signs of lactic acidosis (e.g., malaise, muscle pain, difficulty breathing, abdominal pain, low blood pressure, and slow or irregular heartbeat).

If an overdose is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt to manage a suspected overdose at home. Emergency management may include supportive care and, in cases of significant lactic acidosis, hemodialysis, which is effective in removing metformin and correcting the acidosis. Blood glucose should be monitored closely and treated as clinically indicated.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Oramet Plus should be used with caution in elderly patients, as renal function tends to decrease with age, increasing the risk of metformin-associated lactic acidosis. Renal function should be assessed regularly, and dose selection should be conservative.

Renal impairment

Oramet Plus is contraindicated in patients with significant renal impairment (see Contraindications). Renal function should be evaluated before starting therapy and periodically thereafter.

Hepatic impairment

Oramet Plus should not be used in patients with hepatic impairment or active liver disease, due to increased risk of lactic acidosis and reduced metformin clearance.

Pediatric use

Safety and efficacy of Oramet Plus in pediatric patients have not been established; it is not recommended for use in children (see Pediatric Uses).

Cardiac disease

Oramet Plus is contraindicated in NYHA Class III/IV heart failure and should be used with caution in patients with a history of milder heart failure or other cardiac disease due to fluid retention risk with the rosiglitazone component.

Oramet Plus is generally used as a long-term, ongoing treatment for type 2 diabetes mellitus, as diabetes is a chronic condition requiring continuous management. The duration of treatment should be determined by the prescribing physician based on glycemic control (e.g., HbA1c targets), tolerability, and evolving cardiovascular risk assessment, with regular follow-up visits. Treatment should not be stopped abruptly without medical advice, as this may lead to loss of glycemic control.

Thiazolidinedione + Biguanide combination (Oral Antidiabetic Agent)

Rosiglitazone + Metformin Hydrochloride works through two complementary mechanisms: rosiglitazone activates PPAR-gamma receptors to reduce peripheral insulin resistance and enhance glucose uptake by muscle and fat tissue, while metformin suppresses excessive glucose production by the liver and improves peripheral insulin sensitivity. Neither component directly stimulates pancreatic insulin secretion, so the combination lowers blood glucose without a high intrinsic risk of hypoglycemia when used alone (without insulin or sulfonylureas).

The safety and efficacy of Oramet Plus in pediatric patients (below 18 years of age) have not been established. Oramet Plus is therefore not recommended for use in children and adolescents. Type 2 diabetes in pediatric patients should be managed according to pediatric-specific guidelines, generally with agents that have established pediatric safety and efficacy data, under close specialist supervision.